

099607-081000

des recited in any
s of the foregoing

- (a) polynucleotides recited in any one of SEQ ID NOs:1-81, 313-331, 359, 387 or 391; and
- (b) complements of the foregoing polynucleotides.

g to c
polyn
in an
lynuc

- (a) polynucleotides recited in any one of 1-81, 313-331, 359, 366, 379, 385-389, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 11

(a) polynucleotides recited in any one of SEQ ID NOs:1-81, 319-331, 359, 385-387 or 391; and

(b) complements of the foregoing polynucleotides

- (a) polynucleotides recited in any one of SEQ ID NOs:1-81, 319-331, 359, 385-387 or 391; and
- (b) complements of the foregoing polynucleotides

4. A polynucleotide according to claim 3, wherein the polynucleotide encodes an immunogenic portion of the polypeptide.

5. A polynucleotide according to claim 3, wherein the polynucleotide comprises a sequence recited in any one of SEQ ID NOs:1-81, 319-331, 359, 385-387, 391 or a complement of any of the foregoing sequences.

6. An isolated polynucleotide complementary to a polynucleotide according to claim 3.

7. An expression vector comprising a polynucleotide according to claim 3 or claim 6.

8. A host cell transformed or transfected with an expression vector according to claim 7.

9. A pharmaceutical composition comprising a polypeptide according to claim 1, in combination with a physiologically acceptable carrier.

10. A pharmaceutical composition according to claim 9, wherein the polypeptide comprises an amino acid sequence encoded by a polynucleotide that comprises a sequence recited in any one of SEQ ID NOs:1-81, 313-331, 359, 366, 379, 385-387 or 391.

11. A vaccine comprising a polypeptide according to claim 1, in combination with a non-specific immune response enhancer.

12. A vaccine according to claim 11, wherein the polypeptide comprises an amino acid sequence encoded by a polynucleotide that comprises a sequence recited in any one of SEQ ID NOs:1-81, 313-331, 359, 366, 379, 385-387 or 391.

13. A pharmaceutical composition comprising:

(a) a polynucleotide encoding an ovarian carcinoma polypeptide, wherein the polypeptide comprises at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-81, 319-331, 359, 385-387 or 391; and

(ii) complements of the foregoing polynucleotides; and

(b) a physiologically acceptable carrier.

14. A pharmaceutical composition according to claim 13, wherein the polynucleotide comprises a sequence recited in any one of SEQ ID NOs:1-81, 319-331, 359, 385-387, 391 or a complement of any of the foregoing sequences.

15. A vaccine comprising:

(a) a polynucleotide encoding an ovarian carcinoma polypeptide, wherein the polypeptide comprises at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-81, 313-331, 359, 366, 379, 385-387 or 391; and

(ii) complements of the foregoing polynucleotides; and

16. A vaccine according to claim 15, wherein the polynucleotide comprises a sequence recited in any one of SEQ ID NOs:1-81, 319-331, 359, 385-387 or 391.

17. A pharmaceutical composition comprising:

(a) an antibody that specifically binds to an ovarian carcinoma protein, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-81, 313-331, 359, 366, 379, 385-387 or 391; and

(ii) complements of such polynucleotides; and

(b) a physiologically acceptable carrier.

18. A method for inhibiting the development of ovarian cancer in a patient, comprising administering to a patient an effective amount of an agent selected from the group consisting of:

(a) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of such polynucleotides;

(b) a polynucleotide encoding a polypeptide as recited in (a); and

(c) an antibody that specifically binds to an ovarian carcinoma protein that comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;
and

(ii) complements of such polynucleotides;
and thereby inhibiting the development of ovarian cancer in the patient.

19. A method according to claim 18, wherein the agent is present within a pharmaceutical composition according to any one of claims 9, 13 or 17.

20. A method according to claim 18, wherein the agent is present within a vaccine according to any one of claims 11, 15 or 18.

21. A fusion protein comprising ~~at least~~ one polypeptide according to claim 1.

22. A polynucleotide encoding a fusion protein according to claim 21.

23. A pharmaceutical composition comprising a fusion protein according to claim 21 in combination with a physiologically acceptable carrier.

24. A vaccine comprising a fusion protein according to claim 21 in combination with a non-specific immune response enhancer.

25. A pharmaceutical composition comprising a polynucleotide according to claim 22 in combination with a physiologically acceptable carrier.

26. A vaccine comprising a polynucleotide according to claim 22 in combination with a non-specific immune response enhancer.

27. A method for inhibiting the development of ovarian cancer in a patient, comprising administering to a patient an effective amount of a pharmaceutical composition according to claim 23 or claim 25.

28. A method for inhibiting the development of ovarian cancer in a patient, comprising administering to a patient an effective amount of a vaccine according to claim 23 or claim 26.

29. A pharmaceutical composition, comprising:

(a) an antigen presenting cell that expresses an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of such polynucleotides; and

(b) a pharmaceutically acceptable carrier or excipient.

30. A vaccine, comprising:

(a) an antigen presenting cell that expresses an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

- (ii) complements of such polynucleotides; and
- (b) a non-specific immune response enhancer.

31. A vaccine comprising:

(a) an anti-idiotypic antibody or antigen-binding fragment thereof that is specifically bound by an antibody that specifically binds to an ovarian carcinoma protein that comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;
and

- (ii) complements of such polynucleotides; and
- (b) non-specific immune response enhancer.

32. A vaccine according to claim 30 or claim 31, wherein the immune response enhancer is an adjuvant.

33. A pharmaceutical composition, comprising:

(a) a T cell that specifically reacts with an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;
and

- (ii) complements of such polynucleotides; and
- (b) a physiologically acceptable carrier.

34. A vaccine, comprising:

(a) a T cell that specifically reacts with an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of such polynucleotides; and

(b) a non-specific immune response enhancer.

35. A method for inhibiting the development of ovarian cancer in a patient, comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 29 or claim 33.

36. A method for inhibiting the development of ovarian cancer in a patient, comprising administering to the patient an effective amount of a vaccine according to any one of claims 30, 31 or 34.

37. A method for stimulating and/or expanding T cells, comprising contacting T cells with:

(a) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

- (ii) complements of such polynucleotides;
- (b) a polynucleotide encoding such a polypeptide; and/or
- (c) an antigen presenting cell that expresses such a polypeptide under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

38. A method according to claim 37, wherein the T cells are cloned prior to expansion.

39. A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a pharmaceutical composition comprising:

- (a) one or more of:

- (i) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

- complements of such polynucleotides;

- (ii) a polynucleotide encoding an ovarian carcinoma polypeptide; or
 - (iii) an antigen-presenting cell that expresses an ovarian carcinoma

polypeptide; and

- (b) a physiologically acceptable carrier or excipient;
- and thereby stimulating and/or expanding T cells in a mammal.

40. A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a vaccine comprising:

000780" T 089E960

(a) one or more of:

(i) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

complements of such polynucleotides;

(ii) a polynucleotide encoding an ovarian carcinoma polypeptide; or

(iii) an antigen-presenting cell that expresses an ovarian carcinoma polypeptide; and

(b) a non-specific immune response enhancer;

and thereby stimulating and/or expanding T cells in a mammal.

2 41. A method for inhibiting the development of ovarian cancer in a patient, comprising administering to a patient T cells prepared according to the method of claim 39 or claim 40.

42. A method for inhibiting the development of ovarian cancer in a patient, comprising the steps of:

(a) incubating CD4⁺ T cells isolated from a patient with one or more of:

(i) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian

carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

complements of such polynucleotides;

(ii) a polynucleotide encoding an ovarian carcinoma polypeptide; or

(iii) an antigen-presenting cell that expresses an ovarian carcinoma polypeptide;

such that T cells proliferate; and

(b) administering to the patient an effective amount of the proliferated T cells, and therefrom inhibiting the development of ovarian cancer in the patient.

43. A method for inhibiting the development of ovarian cancer in a patient, comprising the steps of:

(a) incubating CD4⁺ T cells isolated from a patient with one or more of:

(i) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

complements of such polynucleotides;

(ii) a polynucleotide encoding an ovarian carcinoma polypeptide; or

(iii) an antigen-presenting cell that expresses an ovarian carcinoma polypeptide;

such that T cells proliferate;

- (b) cloning one or more proliferated cells; and
- (c) administering to the patient an effective amount of the cloned T cells.

44. A method for inhibiting the development of ovarian cancer in a patient, comprising the steps of:

- (a) incubating CD8⁺ T cells isolated from a patient with one or more of:

- (i) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

- complements of such polynucleotides;

- (ii) a polynucleotide encoding an ovarian carcinoma polypeptide; or

- (iii) an antigen-presenting cell that expresses an ovarian carcinoma polypeptide;

- such that T cells proliferate; and

- (b) administering to the patient an effective amount of the proliferated T cells, and therefrom inhibiting the development of ovarian cancer in the patient.

45. A method for inhibiting the development of ovarian cancer in a patient, comprising the steps of:

- (a) incubating CD8⁺ T cells isolated from a patient with one or more of:

- (i) an ovarian carcinoma polypeptide comprising at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to

react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

complements of such polynucleotides;

(ii) a polynucleotide encoding an ovarian carcinoma polypeptide; or

(iii) an antigen-presenting cell that expresses an ovarian carcinoma polypeptide;

such that the T cells proliferate;

(b) cloning one or more proliferated cells ; and

(c) administering to the patient an effective amount of the cloned T cells.

46. A method for identifying a secreted tumor antigen, comprising the steps of:

(a) implanting tumor cells in an immunodeficient mammal;

(b) obtaining serum from the immunodeficient mammal after a time sufficient to permit secretion of tumor antigens into the serum;

(c) immunizing an immunocompetent mammal with the serum;

(d) obtaining antiserum from the immunocompetent mammal; and

(e) screening a tumor expression library with the antiserum, and therefrom identifying a secreted tumor antigen.

47. A method according to claim 46, wherein the immunodeficient mammal is a SCID mouse and wherein the immunocompetent mammal is an immunocompetent mouse.

48. A method for identifying a secreted ovarian carcinoma antigen, comprising the steps of:

- 09636801.081000
- (a) implanting ovarian carcinoma cells in a SCID mouse;
 - (b) obtaining serum from the SCID mouse after a time sufficient to permit secretion of ovarian carcinoma antigens into the serum;
 - (c) immunizing an immunocompetent mouse with the serum;
 - (d) obtaining antiserum from the immunocompetent mouse; and
 - (e) screening an ovarian carcinoma expression library with the antiserum, and therefrom identifying a secreted ovarian carcinoma antigen.

49. A method for determining the presence or absence of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with a binding agent that binds to an ovarian carcinoma protein, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of the foregoing polynucleotides;

(b) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(c) comparing the amount of polypeptide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

50. A method according to claim 49, wherein the binding agent is an antibody.

51. A method according to claim 50, wherein the antibody is a monoclonal antibody.

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes an ovarian carcinoma protein, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of the foregoing polynucleotides;

(b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

(c) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

58. A method according to claim 57, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.

59. A method according to claim 57, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

60. A method for monitoring the progression of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes an ovarian carcinoma protein, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of the foregoing polynucleotides;

(b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide;

(c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and

(d) comparing the amount of polynucleotide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

61. A method according to claim 60, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.

62. A method according to claim 60, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

63. A diagnostic kit, comprising:

(a) one or more antibodies or antigen-binding fragments thereof that specifically bind to an ovarian carcinoma protein that comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of the foregoing polynucleotides.; and

(b) a detection reagent comprising a reporter group.

64. A kit according to claim 63, wherein the antibodies are immobilized on a solid support.

65. A kit according to claim 63, wherein the solid support comprises nitrocellulose, latex or a plastic material.

66. A kit according to claim 63, wherein the detection reagent comprises an anti-immunoglobulin, protein G, protein A or lectin.

67. A kit according to claim 63, wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

68. A diagnostic kit, comprising:

(a) an oligonucleotide comprising 10 to 40 nucleotides that hybridize under moderately stringent conditions to a polynucleotide that encodes an ovarian carcinoma protein; wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs:1-387 or 391;

and

(ii) complements of the foregoing polynucleotides; and

(b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.

69. An ovarian carcinoma polypeptide, comprising the sequence of O8E as depicted by SEQ ID NO: 392.

70. An ovarian carcinoma polypeptide, comprising the sequence of O8E as depicted by SEQ ID NO: 393.

71. An antibody epitope of O8E wherein said antibody epitope is selected from the group consisting of SEQ ID NO: 394-414 and 415.

add
B3

79